



Contents lists available at ScienceDirect

Tetrahedron Letters

journal homepage: www.elsevier.com/locate/tetlet

Rhamnose-based glycomimetic for recruitment of endogenous anti-rhamnose antibodies

Nives Hribernik^{a,c}, Fabrizio Chiodo^{b,d}, Roland J. Pieters^c, Anna Bernardi^{a,*}^a Università degli Studi di Milano, Dipartimento di Chimica, via Golgi 19, 20133 Milano, Italy^b Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam 1081HV, The Netherlands^c Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, P.O. Box 80082, NL-3508 TB Utrecht, The Netherlands^d Institute of Biomolecular Chemistry, National Research Council (CNR), Pozzuoli 80078, Napoli, Italy

ARTICLE INFO

Article history:

Received 24 February 2022

Revised 25 April 2022

Accepted 28 April 2022

Available online xxxxx

Keywords:

L-Rhamnose

Anti-carbohydrate antibodies

Glycomimetics

Immunotherapy

ABSTRACT

Recruitment of natural antibodies towards tumour cells for their elimination by the immune system could be a highly specific and efficacious therapeutic strategy. While natural L-rhamnose has already been explored as a suitable antigen for antibody recruitment, we here report the first rhamnose-based glycomimetic to be used for such purpose. The glycomimetic is designed to be more hydrolytically and enzymatically stable than natural rhamnosides, provides a site for easy further conjugation and proved to capture anti-rhamnose IgG antibodies in serological ELISA assay.

© 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Utilizing the immune system to combat diseases, such as cancer, can be a particularly specific and efficacious therapeutic strategy. Although significant progress has been made in surgery, chemo- and radiotherapy, we are still on the lookout for new cancer treatment approaches that could improve long-term survival and tolerability. An interesting novel idea is based on selective labelling of tumour cells with compounds able to recruit naturally produced antibodies, which then activates the immune system and ultimately leads to destruction of these cells.

The destruction of malignant cells happens through two antibody effector mechanisms: complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) [1–4]. CDC is based mainly on IgM type antibodies, their recruitment leads to activation of the classical complement cascade. Subsequently, signalling molecules such as cytokines and inflammatory mediators are released. These signalling molecules then attract neutrophils, macrophages, and natural killer cells that are involved in ADCC. Immune effector cells recognize IgG antibodies bound to the cell surface and initiate ADCC through activation of Fc receptors [4].

Endogenous antibodies could be recruited towards tumour cells with the help of a so called antibody recruiting molecule that consists of an antibody binding module and a tumour binding module as shown in Fig 1 [5]. The function of the tumour binding module is to specifically recognize and bind to epitopes only present on the surface of tumour cells. Upon binding of the antibody recruiting molecule to the tumour cells, the antibody binding module is then presented on the surface of those cells. The antibody binding module on the other hand should contain an antigen that is recognized by antibodies and subsequently directs them towards tumour cells. There are three main criteria for an ideal antigen for this purpose [4]. First, the antigen has to be readily accessible or easy to synthesize and it should be possible to conjugate it to the tumour binding module. Second, it is considered a significant advantage if the antigen binds endogenous antibodies, because those are present even in partially immunocompromised individuals. Finally, the antigen should preferably bind antibodies of both IgG and IgM isotype, so that it can use both CDC and ADCC effector mechanisms.

Several potential antigens have been identified, for example dinitrophenyl (DNP), galactose- α -1,3-D-galactose (α Gal) and α -L-rhamnose (α Rha) (Fig. 2). DNP is a small molecule that is immunogenic and can be easily manipulated, however natural anti-DNP antibodies are present only in low concentrations [6–8]. Additionally, DNP can non-specifically interact with membranes and albumins, which limits its potential as an antigen [9–10]. As an alternative, α Gal is a natural antigenic epitope present in most

* Corresponding author.

E-mail address: anna.bernardi@unimi.it (A. Bernardi).

<https://doi.org/10.1016/j.tetlet.2022.153843>

0040-4039/© 2022 The Author(s). Published by Elsevier Ltd.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Antibody recruiting molecule




Fig. 1. The antibody recruiting molecule consists of two modules: a) antibody binding module and b) tumour binding module.




Fig. 2. Potential antigens for endogenous antibody recruitment: a) galactose- α -D-1,3-galactose (α Gal), b) α -L-rhamnose (α Rha), c) dinitrophenyl (DNP), d) rhamnose based glycomimetic used in this study.

mammals and bacteria, yet absent in humans and therefore recognized as foreign [11–12]. Due to constant exposure to endogenous gut bacteria, anti-Gal antibodies actually represent approximately 2% of circulating IgG and 3–8% of serum IgM in humans [13–15]. A significant drawback of utilizing α Gal for antibody recruitment however is its synthetic complexity, both for chemical and chemoenzymatic synthesis [16–19]. Finally, the α Rha epitope is, similar to α Gal, common in microbes and plants and absent in humans [20–22]. In fact, it has been reported that anti-Rha antibodies are the most abundant and prevalent anti-carbohydrate antibodies in human serum [23–24]. The exposure of tumour cells to rhamnose-bearing glycolipids and human serum also promotes complement-mediated cytotoxicity [4]. This shows that α Rha is an excellent candidate for further development in immune system recruitment strategies.

In addition to antibody recruitment for tumour cell elimination, it has been proposed that a rhamnose binding lectin is present on the surface of malignant cell lines [25]. Such lectin was found for instance on the surface of normal human dermal fibroblasts (NHDFs) and human umbilical venous endothelial cells (HUVEC) [26–27]. Therefore, α Rha could also play an important role in anti-

tumour activity by binding to the rhamnose binding receptor of certain cell lines [25].


Previously, several groups successfully constructed rhamnosides for recruitment of natural antibodies. For example, α Rha functionalized liposomes were developed for selective tumour cell targeting [28]. Such system works on the basis of multivalent amplification of low-affinity interactions between carbohydrates and antibodies that lead to efficient recognition of cancer cells by the immune system [29–30]. Further, α Rha can be incorporated onto the scaffolds of cytotoxic agents, for example betulinol 3,28-di-O- α -L-rhamnopyranoside and betulinic acid 3-O- α -L-rhamnopyranoside display antitumor activity [31–33]. Rhamnose derivatives of anthracenes [34–35], steroids [36] and saponins [37] also showed cytotoxicity.

While rhamnose-based constructs clearly show the potential as anticancer therapeutics, the carbohydrate nature of α Rha is inherently linked to certain drawbacks, such as low affinity and metabolic instability. To overcome the low affinity of rhamnose-antibody interactions, multivalent systems can amplify the impact with the so-called cluster effect [38–39]. In fact, the importance of multivalent presentation of α Rha for efficient recognition with natural IgM antibodies was demonstrated [5], leading to the development of different multivalent rhamnose-based glycoconjugates [5,40]. Still, all previously developed constructs utilized natural α Rha, which is, as all natural saccharides, sensitive to enzymatic and acid-catalysed hydrolysis. Therefore, we here report the synthesis and serological evaluation of a rhamnose-based glycomimetic antigen (Fig. 2) with an improved metabolic stability, equipped with a site for easy conjugation to multivalent systems and/or tumour binding module.

Results and discussion

As described above, all previous constructs utilized natural α Rha and conjugated it to the scaffold through an O-linkage, which is sensitive to enzymatic hydrolysis. We therefore decided to rather introduce an S-linkage which is known to be significantly more resistant towards glycosidases [41]. Our group has previously shown that pseudo-thio-dimannoside is an excellent mimic of the natural dimannoside epitope in the development of DC-SIGN ligands [42], thus confirming that due to similar bonding and geometry, the anomeric oxygen can in fact be replaced with a sulphur atom.

Working with S-glycosides is also synthetically advantageous as they are often easier to synthesize. In fact, we previously developed a one-pot synthetic procedure for synthesis of N-linked pseudo-thio-glycosides, including rhamnoside **3** as shown in Scheme 1 [43]. In this procedure the peracetylated rhamnosyl thioacetate **1** is deacetylated *in situ* at the anomeric position by excess amount of Et₂NH. This generates a thiolate able to open the aziridine **2**. The product **3** is formed as a single compound from a selective *trans*-diaxial aziridine opening in an excellent 92% yield. The reaction is carried out as a one-pot procedure at room temperature and is thus facile and operationally simpler than classic gly-



Scheme 1. One-pot aziridine opening reaction for the synthesis of rhamnoside **3**.

cosylation methods. The rhamnoside **3** is equipped with an aglycone that can assist its binding and contains an *N*-linkage for simple conjugation to multivalent scaffolds or directly to the tumour binding module. The α -anomeric configuration of the Rha derivative **3** was established on the basis of the NOESY experiment and the measured J_{H1-C1} HSQC NMR without ^{13}C decoupling [43].


To prove that the glycomimetic **3** can in fact be used for further conjugation and for the purpose of biological evaluation by ELISA assay, a multivalent construct **10** was then synthesized from the thio-rhamno conjugate **3** as shown in Scheme 2. The design of **10** includes a hydrophobic tail, to allow immobilization of the structure on an ELISA plate, and three copies of the thio-rhamnoside ligand, to generate a minimal cluster effect. For its synthesis, after Boc deprotection of **3** (TFA, quant), the resulting amine **4** was coupled with 5-azido-valeric acid **5** using HATU as the coupling agent to give **6** in 87% yield. On the other hand, the tetravalent alkyne **8** was synthesized from pentaeritritol with propargyl bromide and treated with 10-azidodecane **7** to afford the trivalent alkyne **9** in 35% yield. The monovalent rhamnose-azide conjugate **6** was then

used in a click reaction with **9** using CuI/CH₃CN and the final multivalent construct **10** was obtained in 29% yield after deacetylation of hydroxyl groups with MeNH₂/THF and purification with size exclusion chromatography on P2 gel with eluent H₂O:MeOH 1:1.


As a negative control we synthesized a dendrimer **12** by esterification of **5** with triethylene glycol followed by a click reaction of **11** with **9** to afford **12** in 22% yield upon purification with size exclusion chromatography on P2 gel with eluent H₂O:MeOH 1:1 (Scheme 3).

A serological ELISA assay with 12 human samples from healthy donors was then performed adapting a protocol from a similar study [44]. This solid phase assay was designed to prove the ability of the rhamnosylated construct in capturing anti-Rha IgG antibodies.

Briefly, the ELISA plate was coated with product **10** or **12** and after a blocking step, the wells were incubated with human plasma. After washing, an anti-human IgG antibody conjugated with horseradish peroxidase was added to the wells. A last washing step was then performed followed by the addition of the chro-



Scheme 2. Synthesis of multivalent construct **10** from the thio-rhamno conjugate **3**.



Scheme 3. Synthesis of dendrimer **12** that was used as negative control in the ELISA experiment.




Fig. 3. Human IgG in plasma detected by coating ELISA plates with the mentioned dendrimer (n = 12, biologically independent samples). Ordinary two-way ANOVA with an alpha significance level of 0.05 was used with Prism GraphPad version 6.0. P ≤ 0.01 is indicated with **. OD, optical density.

mogenic substrate. The readout of the wells was done reading the plate at 450 nm. Fig. 3 showed the binding results: dendrimer **12** was able to capture anti-Rha IgG while the control dendrimer **10** showed a significant lower binding. These results proved that den-

dimer **10** could be explored to target anti-Rha IgG for vaccination strategies.

Conclusions

As the search for novel strategies to combat cancer continues, immunotherapy certainly shines as one of the most promising options. The utility of synthetic chemistry in immunotherapy has already been demonstrated through development of antitumoral vaccines, yet immunization of immunocompromised cancer patients is often inefficient. Therefore, it appears to be more suitable to use a synthetic molecule that would direct the endogenous antibodies towards tumour cells. We herein report the first rhamnose-based glycomimetic that can be potentially used as the antibody binding module for such purpose. In comparison to the natural α Rha epitope, the glycomimetic is designed to be more enzymatically and hydrolytically stable and equipped with an aglycone that allows simple conjugation to tumour binding module or multivalent scaffold. This study sets the stage for the development of a second generation of rhamnose-based glycomimetics to be used for antibody recruitment.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

Funding: This research was funded by the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 765581 (PhD4GlycoDrug).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.tetlet.2022.153843>.

References

- [1] A. Natsume, R. Niwa, M. Satoh, *Drug Des. Dev. Ther.* 3 (2009) 7–16.
- [2] D. Berd, *Vaccine* 19 (2001) 2565–2570.
- [3] U. Galili, M.R. Albertini, P.M. Sondel, K. Wigglesworth, M. Sullivan, G.F. Whalen, *Cancers* (2010) 2.
- [4] R.T.C. Sheridan, J. Hudon, J.A. Hank, P.M. Sondel, L.L. Kiessling, *ChemBioChem* 15 (2014) 1393–1398.
- [5] B. Liet, E. Laigre, D. Goyard, B. Todaro, C. Tiertant, D. Boturyn, N. Berthet, O. Renaudet, *Chemistry – A European Journal* 25 (2019) 15508–15515.
- [6] F.S. Farah, Z.L. Awdeh, *J. Immunol. Methods* 1 (1972) 353–361.
- [7] R.P. Murelli, A.X. Zhang, J. Michel, W.L. Jorgensen, D.A. Spiegel, *J. Am. Chem. Soc.* 131 (2009) 17090–17092.
- [8] C.G. Parker, R.A. Domaal, K.S. Anderson, D.A. Spiegel, *J. Am. Chem. Soc.* 131 (2009) 16392–16394.
- [9] A.X. Zhang, R.P. Murelli, C. Barinka, J. Michel, A. Cocleaza, W.L. Jorgensen, J. Lubkowski, D.A. Spiegel, *J. Am. Chem. Soc.* 132 (2010) 12711–12716.
- [10] H. Jung, T. Yang, M.D. Lasagna, J. Shi, G.D. Reinhart, P.S. Cremer, *Biophys. J.* 94 (2008) 3094–3103.
- [11] U. Galili, M.R. Clark, S.B. Shohet, J. Buehler, B.A. Macher, *Proc. Natl. Acad. Sci.* 84 (1987) 1369.
- [12] U. Galili, S.B. Shohet, E. Kobrin, C.L. Stults, B.A. Macher, *J. Biol. Chem.* 263 (1988) 17755–17762.
- [13] U. Galili, R.E. Mandrell, R.M. Hamadeh, S.B. Shohet, J.M. Griffiss, *Infect. Immun.* 56 (1988) 1730–1737.
- [14] U. Galili, E.A. Rachmilewitz, A. Peleg, I. Flechner, *J. Exp. Med.* 160 (1984) 1519–1531.
- [15] W. Parker, D. Bruno, Z.E. Holzkecht, J.L. Platt, *J. Immunol.* 153 (1994) 3791.
- [16] R.M. Owen, C.B. Carlson, J. Xu, P. Mowery, E. Fasella, L.L. Kiessling, *ChemBioChem* 8 (2007) 68–82.
- [17] C. Gege, W. Kinzy, R.R. Schmidt, *Carbohydr. Res.* 328 (2000) 459–466.
- [18] K.P. Naicker, H. Li, A. Heredia, H. Song, L.-X. Wang, *Org. Biomol. Chem.* 2 (2004) 660–664.
- [19] J. Fang, J. Li, X. Chen, Y. Zhang, J. Wang, Z. Guo, W. Zhang, L. Yu, K. Brew, P.G. Wang, *J. Am. Chem. Soc.* 120 (1998) 6635–6638.
- [20] V. Martinez, M. Ingwers, J. Smith, J. Glushka, T. Yang, M. Bar-Peled, *J. Biol. Chem.* 287 (2012) 879–892.
- [21] S.D. Bentley, D.M. Aanensen, A. Mavroidi, D. Saunders, E. Rabinowitsch, M. Collins, K. Donohoe, D. Harris, L. Murphy, M.A. Quail, G. Samuel, I.C. Skovsted, M.S. Koltso, B. Barrell, P.R. Reeves, J. Parkhill, B.G. Spratt, *PLoS Genet.* 2 (2006) e31.
- [22] G. Samuel, P. Reeves, *Carbohydr. Res.* 338 (2003) 2503–2519.
- [23] O. Oyelaran, L.M. McShane, L. Dodd, J.C. Gildersleeve, J. Proteome Res. 8 (2009) 4301–4310.
- [24] M.E. Huflejt, M. Vuskovic, D. Vasiliu, H. Xu, P. Obukhova, N. Shilova, A. Tuzikov, O. Galanina, B. Arun, K. Lu, N. Bovin, *Mol. Immunol.* 46 (2009) 3037–3049.
- [25] Y. Wang, J. Gao, G. Gu, G. Li, C. Cui, B. Sun, H. Lou, *ChemBioChem* 12 (2011) 2418–2420.
- [26] H. Tateno, A. Saneyoshi, T. Ogawa, K. Muramoto, H. Kamiya, M. Saneyoshi, *J. Biol. Chem.* 273 (1998) 19190–19197.
- [27] G. Faury, E. Ruszova, J. Molinari, B. Mariko, S. Raveaud, V. Velebny, L. Robert, *BBA* 1780 (2008) 1388–1394.
- [28] X. Li, X. Rao, L. Cai, X. Liu, H. Wang, W. Wu, C. Zhu, M. Chen, P.G. Wang, W. Yi, *ACS Chem. Biol.* 11 (2016) 1205–1209.
- [29] C.B. Carlson, P. Mowery, R.M. Owen, E.C. Dykhuizen, L.L. Kiessling, *ACS Chem. Biol.* 2 (2007) 119–127.
- [30] L.L. Kiessling, J.E. Gestwicki, L.E. Strong, *Curr. Opin. Chem. Biol.* 4 (2000) 696–703.
- [31] C. Gauthier, J. Legault, S. Lavoie, S. Rondeau, S. Tremblay, A. Pichette, *J. Nat. Prod.* 72 (2009) 72–81.
- [32] M. Mihoub, A. Pichette, B. Sylla, C. Gauthier, J. Legault, *PLoS ONE* 13 (2018) e0193386.
- [33] C. Gauthier, J. Legault, M. Lebrun, P. Dufour, A. Pichette, *Bioorg. Med. Chem.* 14 (2006) 6713–6725.
- [34] G. Song, H. Liu, W. Zhang, M. Geng, Y. Li, *Bioorg. Med. Chem.* 18 (2010) 5183–5193.
- [35] J.-Y. Xing, G.-P. Song, J.-P. Deng, L.-Z. Jiang, P. Xiong, B.-J. Yang, S.-S. Liu, *PLoS ONE* 10 (2015) e0144781.
- [36] B.E. Cham, T.R. Chase, *Planta Med* 78 (2012) 349–353.
- [37] Y. Wang, Y. Zhang, B. Yu, *ChemMedChem* 2 (2007) 288–291.
- [38] C. Fasting, C.A. Schalley, M. Weber, O. Seitz, S. Hecht, B. Kokschi, J. Darnedde, C. Graf, E.-W. Knapp, R. Haag, *Angew. Chem. Int. Ed.* 51 (2012) 10472–10498.
- [39] S. Cecioni, A. Imberty, S. Vidal, *Chem. Rev.* 115 (2015) 525–561.
- [40] J. Alsarraf, P. Gormand, J. Legault, M. Mihoub, A. Pichette, *Tetrahedron Lett.* 61 (2020) 151706.
- [41] H. Driguez, *ChemBioChem* 2 (2001) 311–318.
- [42] A. Tamburrini, S. Achilli, F. Vasile, S. Sattin, C. Vivès, C. Colombo, F. Fieschi, A. Bernardi, *Bioorg. Med. Chem.* 25 (2017) 5142–5147.
- [43] N. Hribernik, A. Tamburrini, E. Falletta, A. Bernardi, *Org. Biomol. Chem.* 19 (2021) 233–247.
- [44] X. Wang, H. Chen, F. Chiodo, B. Tefsen, *Matters*, 2019.